Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Ipca Laboratories Ltd
Quarter-by-quarter operating performance
| Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 1,546 | 1,512 | 1,585 | 2,034 | 2,053 | 2,033 | 2,093 | 2,355 | 2,245 | 2,247 | 2,309 | 2,556 | 2,392 |
| Expenses + | 1,330 | 1,331 | 1,278 | 1,673 | 1,722 | 1,711 | 1,700 | 1,913 | 1,782 | 1,818 | 1,892 | 2,012 | 1,859 |
| Operating Profit | 216 | 181 | 308 | 361 | 331 | 322 | 393 | 441 | 463 | 429 | 416 | 545 | 533 |
| OPM % | 14% | 12% | 19% | 18% | 16% | 16% | 19% | 19% | 21% | 19% | 18% | 21% | 22% |
| Other Income + | 31 | 36 | 45 | -1 | 91 | -118 | 21 | 26 | 20 | -179 | 33 | -30 | 38 |
| Interest | 11 | 18 | 31 | 44 | 33 | 29 | 24 | 23 | 17 | 22 | 19 | 20 | 18 |
| Depreciation | 67 | 70 | 69 | 90 | 100 | 98 | 99 | 100 | 98 | 100 | 100 | 103 | 108 |
| Profit before tax | 169 | 129 | 252 | 225 | 289 | 77 | 290 | 345 | 368 | 128 | 331 | 392 | 446 |
| Tax % | 32% | 37% | 34% | 39% | 23% | 96% | 31% | 29% | 25% | 49% | 29% | 28% | 18% |
| Net Profit + | 110 | 78 | 164 | 136 | 221 | 1 | 199 | 246 | 276 | 64 | 233 | 281 | 364 |
| EPS in Rs | 4.25 | 3.02 | 6.42 | 5.72 | 7.09 | 2.35 | 7.58 | 9.05 | 9.78 | 2.67 | 9.19 | 11.14 | 12.86 |
Financials of Ipca Laboratories Ltd
Annual income statement trend
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 3,282 | 3,144 | 2,867 | 3,156 | 3,258 | 3,746 | 4,619 | 5,395 | 5,797 | 6,204 | 7,662 | 8,897 | 9,505 |
| Expenses + | 2,539 | 2,604 | 2,573 | 2,705 | 2,803 | 3,051 | 3,715 | 3,843 | 4,472 | 5,272 | 6,338 | 7,166 | 7,581 |
| Operating Profit | 743 | 541 | 294 | 451 | 455 | 695 | 904 | 1,552 | 1,325 | 932 | 1,324 | 1,731 | 1,924 |
| OPM % | 23% | 17% | 10% | 14% | 14% | 19% | 20% | 29% | 23% | 15% | 17% | 19% | 20% |
| Other Income + | 21 | 32 | 21 | 11 | 41 | 56 | 65 | 59 | 54 | 123 | 17 | -114 | -139 |
| Interest | 30 | 32 | 35 | 27 | 28 | 22 | 20 | 12 | 11 | 48 | 141 | 88 | 77 |
| Depreciation | 103 | 180 | 163 | 173 | 178 | 182 | 210 | 209 | 232 | 262 | 357 | 398 | 411 |
| Profit before tax | 631 | 361 | 117 | 262 | 291 | 546 | 739 | 1,389 | 1,136 | 745 | 843 | 1,131 | 1,296 |
| Tax % | 24% | 28% | 18% | 26% | 18% | 19% | 18% | 17% | 20% | 34% | 37% | 30% | |
| Net Profit + | 479 | 254 | 93 | 195 | 239 | 442 | 604 | 1,141 | 890 | 479 | 523 | 785 | 941 |
| EPS in Rs | 18.96 | 10.07 | 3.69 | 7.71 | 9.49 | 17.60 | 23.99 | 44.94 | 34.85 | 18.58 | 21.57 | 29.08 | 35.86 |
| Dividend Payout % | 13% | 5% | 0% | 6% | 5% | 9% | 10% | 9% | 11% | 22% | 19% | 14% |
Financials of Ipca Laboratories Ltd
Capital structure and asset base
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 |
| Reserves | 1,934 | 2,183 | 2,234 | 2,430 | 2,663 | 3,097 | 3,602 | 4,676 | 5,439 | 5,817 | 6,307 | 6,923 | 7,402 |
| Borrowings + | 603 | 935 | 867 | 716 | 628 | 465 | 501 | 265 | 807 | 1,481 | 1,438 | 1,363 | 1,279 |
| Other Liabilities + | 648 | 669 | 765 | 788 | 799 | 961 | 1,130 | 1,099 | 1,349 | 1,300 | 3,326 | 3,432 | 3,557 |
| Total Liabilities | 3,211 | 3,812 | 3,892 | 3,960 | 4,116 | 4,549 | 5,258 | 6,066 | 7,622 | 8,623 | 11,097 | 11,744 | 12,263 |
| Fixed Assets + | 1,354 | 1,800 | 2,014 | 1,983 | 1,953 | 1,940 | 2,059 | 2,072 | 2,402 | 2,751 | 4,554 | 4,267 | 4,371 |
| CWIP | 165 | 267 | 129 | 95 | 73 | 66 | 133 | 235 | 306 | 140 | 343 | 622 | 777 |
| Investments | 9 | 16 | 26 | 136 | 87 | 120 | 310 | 505 | 989 | 626 | 862 | 980 | 1,203 |
| Other Assets + | 1,683 | 1,729 | 1,723 | 1,746 | 2,003 | 2,422 | 2,756 | 3,254 | 3,924 | 5,105 | 5,339 | 5,875 | 5,912 |
| Total Assets | 3,211 | 3,812 | 3,892 | 3,960 | 4,116 | 4,549 | 5,258 | 6,066 | 7,622 | 8,623 | 11,097 | 11,744 | 12,263 |
Financials of Ipca Laboratories Ltd
Operating, investing and financing cash movement
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 522 | 468 | 709 | 282 | 341 | 501 | 570 | 1,090 | 856 | 806 | 945 | 1,321 |
| Cash from Investing Activity + | -369 | -689 | -218 | -149 | -135 | -165 | -509 | -521 | -851 | -725 | -1,215 | -870 |
| Cash from Financing Activity + | -136 | 251 | -462 | -159 | -130 | -183 | -137 | -306 | 427 | 507 | -553 | -283 |
| Net Cash Flow | 18 | 29 | 29 | -26 | 75 | 153 | -76 | 264 | 432 | 588 | -823 | 169 |
| Free Cash Flow | 144 | -207 | 463 | 147 | 206 | 322 | 277 | 731 | 380 | 347 | 543 | 551 |
| CFO/OP | 88% | 100% | 251% | 74% | 88% | 88% | 80% | 86% | 80% | 110% | 94% | 97% |
Financials of Ipca Laboratories Ltd
Working capital efficiency and return ratios
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 50 | 41 | 57 | 58 | 67 | 66 | 71 | 55 | 57 | 58 | 80 | 77 |
| Inventory Days | 272 | 293 | 289 | 290 | 286 | 316 | 294 | 337 | 337 | 276 | 350 | 336 |
| Days Payable | 110 | 97 | 145 | 130 | 137 | 154 | 135 | 140 | 101 | 83 | 110 | 111 |
| Cash Conversion Cycle | 213 | 237 | 200 | 218 | 216 | 228 | 229 | 251 | 293 | 251 | 321 | 302 |
| Working Capital Days | 82 | 68 | 61 | 74 | 80 | 88 | 88 | 103 | 102 | 71 | 111 | 101 |
| ROCE % | 28% | 14% | 5% | 9% | 10% | 16% | 19% | 31% | 20% | 11% | 13% | 15% |